On December 5, 2025, XTL Biopharmaceuticals Ltd. (the " Company") announced that effective December 11, 2025, Mr. Itay Weinstein resigned from his position as Chief Financial Officer of the Company. Mr. Weinstein resignation was not a result of any disagreement with the Company or its management.
To fill in the vacancy created by the resignation of Mr. Weinstein, on November 30, 2025, the Board of Directors of the Company approved the appointment of Mr. Niv Segal as the Company's Chief Financial Officer instead of Mr. Weinstein.
Mr. Segal, CPA, has over 12 years of senior financial management experience, primarily in the high-tech sector. He served as the Chief Financial Officer of G.S. Innplay Labs, where he led the company's $300M acquisition by Playtika, and as the Chief Financial Officer of Beach Bum, managing its $700M acquisition process. Earlier, Mr. Segal was the Group Corporate Controller at Gix Ltd. ((TASE: GIX, NASDAQ: VBIX), overseeing global finance operations, public company reporting, M&A processes, and SOX compliance. Mr. Segal began his career at PwC Israel, auditing public and private companies. Mr. Segal holds an MBA in Accounting, a BA in Economics and Accounting, and is a Certified Public Accountant in Israel.
On December 5, 2025, XTL Biopharmaceuticals Ltd. (the " **Company**") announced that effective December 11, 2025, Mr. Itay Weinstein resigned from his position as Chief Financial Officer of the Company. Mr. Weinstein resignation was not a result of any disagreement with the Company or its management.
To fill in the vacancy created by the resignation of Mr. Weinstein, on November 30, 2025, the Board of Directors of the Company approved the appointment of Mr. Niv Segal as the Company's Chief Financial Officer instead of Mr. Weinstein.
Mr. Segal, CPA, has over 12 years of senior financial management experience, primarily in the high-tech sector. He served as the Chief Financial Officer of G.S. Innplay Labs, where he led the company's $300M acquisition by Playtika, and as the Chief Financial Officer of Beach Bum, managing its $700M acquisition process. Earlier, Mr. Segal was the Group Corporate Controller at Gix Ltd. ((TASE: GIX, NASDAQ: VBIX), overseeing global finance operations, public company reporting, M&A processes, and SOX compliance. Mr. Segal began his career at PwC Israel, auditing public and private companies. Mr. Segal holds an MBA in Accounting, a BA in Economics and Accounting, and is a Certified Public Accountant in Israel.
<p>On December 5, 2025, XTL Biopharmaceuticals Ltd. (the "<strong>Company</strong>") announced that effective December 11, 2025, Mr. Itay Weinstein resigned from his position as Chief Financial Officer of the Company. Mr. Weinstein resignation was not a result of any disagreement with the Company or its management.</p><p>To fill in the vacancy created by the resignation of Mr. Weinstein, on November 30, 2025, the Board of Directors of the Company approved the appointment of Mr. Niv Segal as the Company's Chief Financial Officer instead of Mr. Weinstein.</p><p>Mr. Segal, CPA, has over 12 years of senior financial management experience, primarily in the high-tech sector. He served as the Chief Financial Officer of G.S. Innplay Labs, where he led the company's $300M acquisition by Playtika, and as the Chief Financial Officer of Beach Bum, managing its $700M acquisition process. Earlier, Mr. Segal was the Group Corporate Controller at Gix Ltd. ((TASE: GIX, NASDAQ:<a href="https://www.benzinga.com/quote/VBIX">VBIX</a>), overseeing global finance operations, public company reporting, M&A processes, and SOX compliance. Mr. Segal began his career at PwC Israel, auditing public and private companies. Mr. Segal holds an MBA in Accounting, a BA in Economics and Accounting, and is a Certified Public Accountant in Israel.</p>